Cargando…
5-Methoxytryptophan Sensitizing Head and Neck Squamous Carcinoma Cell to Cisplatitn Through Inhibiting Signal Transducer and Activator of Transcription 3 (STAT3)
Head and neck squamous cell carcinoma (HNSCC) is a common cancer of the oral cavity. Cisplatin (CDDP) is the ideal chemo-radiotherapy used for several tumor types, but resistance to the drug has become a major obstacle in treating patients with HNSCC. 5-methoxytryptophan (5-MTP), a 5-methoxyindole m...
Autores principales: | Su, Yu-Chieh, Wang, Chih-Chun, Weng, Jui-Hsi, Yeh, Shyh-An, Chen, Po-Jen, Hwang, Tzer-Zen, Chen, Huang-Chi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353643/ https://www.ncbi.nlm.nih.gov/pubmed/35936759 http://dx.doi.org/10.3389/fonc.2022.834941 |
Ejemplares similares
-
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
por: Chuang, Fu-Cheng, et al.
Publicado: (2021) -
Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
por: Su, Yu-Chieh, et al.
Publicado: (2022) -
A Novel Protective Function of 5-Methoxytryptophan in Vascular Injury
por: Ho, Yen-Chun, et al.
Publicado: (2016) -
5-methoxytryptophan: an arsenal against vascular injury and inflammation
por: Wu, Kenneth K., et al.
Publicado: (2020) -
Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)